Chinese General Practice ›› 2019, Vol. 22 ›› Issue (12): 1501-1506.DOI: 10.12114/j.issn.1007-9572.2018.00.321
Special Issue: 内分泌代谢性疾病最新文章合辑
• Monographic Research • Previous Articles Next Articles
Published:
2019-04-20
Online:
2019-04-20
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2018.00.321
[1]贾建平.中国痴呆与认知障碍诊治指南(2015年版)[M].北京:人民卫生出版社,2015:1. JIA J P.Guidelines for diagnosis and treatment of dementia and cognitive impairment in China (2015 Edition)[M].Beijing:People's Medical Publishing House,2015:1. [2]FERRI C P,PRINCE M,BRAYNE C,et al.Global prevalence of dementia:a Delphi consensus study[J].Lancet,2005,366(9503):2112-2117.DOI:10.1016/S0140-6736(05)67889-0. [3]FENG Q P,LI X J,SU Y,et al.Study on the relation of TCF7L2rs7903146T/C and rs7901695T/C SNPs with susceptibility to type 2 diabetes mellitus in Inner Mongolia Han people[J].Chinese Journal of Diabetes,2012,20(10):721-724.DOI:10.3969/j.issn.1006-6187.2012.10.001. [4]WENNBERG A M,GOTTESMAN R F,KAUFMANN C N,et al. Diabetes and cognitive outcomes in a nationally representative sample:the National Health and Aging Trends Study[J].Int Psychogeriatr,2014,26(10):1729-1735.DOI:10.1017/S1041610214001380. [5]GUDALA K,BANSAL D,SCHIFANO F,et al.Diabetes mellitus and risk of dementia:a meta-analysis of prospective observational studies[J].J Diabetes Investig,2013,4(6):640-650.DOI:10.1111/jdi.12087. [6]LI L,WANG Y,YAN J,et al.Clinical predictors of cognitive decline in patients with mild cognitive impairment:the Chongqing aging study[J].J Neurol,2012,259(7):1303-1311.DOI:10.1007/s00415-011-6342-0. [7]LI L,HOLSCHER C.Common pathological processes in Alzheimer disease and type 2 diabetes:a review[J].Brain Res Rev,2007,56(2):384-402.DOI:10.1016/j.brainresrev.2007.09.001. [8]MOHEET A,MANGIA S,SEAQUIST E R.Impact of diabetes on cognitive function and brain structure[J].Ann N Y Acad Sci,2015,1353:60-71.DOI:10.1111/nyas.12807. [9]PALTA P,SCHNEIDER A L,BIESSELS G J,et al.Magnitude of cognitive dysfunction in adults with type 2 diabetes:a meta-analysis of six cognitive domains and the most frequently reported neuropsychological tests within domains[J].Int Neuropsychol Soc,2014,20(3):278-291.DOI:10.1017/S1355617713001483. [10]MANSCHOT S M,BRANDS A M,VAN DER GROND J,et al.Brain magnetic resonance imaging correlates of impaired cognition in patients with type 2 diabetes[J].Diabetes,2006,55(4):1106-1113. [11]LOURIDA I,SONI M,THOMPSON-COON J,et al.Mediterranean diet,cognitive function,and dementia:a systematic review[J].Epidemiology ,2013,24:479-489.DOI:10.1097/EDE.0b013e3182944410. [12]FOTUHI M,MOHASSEL P,YAFFE K.Fish consumption,long-chain omega-3 fatty acids and risk of cognitive decline or Alzheimer disease:a complex association[J].Nat Clin PractNeurol,2009,5:140-152.DOI:10.1038/ncpneuro1044. [13]BLASKO I,HINTERBERGER M,KEMMLER G,et al.Conversion from mild cognitive impairment to dementia:influence of folic acid and vitamin B12 use in the VITA cohort[J].Nutr Health Aging,2012,16(8):687-694.DOI:10.1007/s12603-012-0051-y. [14]DEVORE E E,KANG J H,BRETELER M M,et al.Dietary intakes of berries and flavonoids in relation to cognitive decline[J].Ann Neurol,2012,72(1):135-143.DOI:10.1002/ana.23594. [15]VOSS M W,VIVAR C,KRAMER A F,et al.Bridging animal and human models of exercise-induced brain plasticity[J].Trends Cogn Sci,2013,17(10):525-544.DOI:10.1016/j.tics.2013.08.001. [16]Look AHEAD Research Group,WING R R.Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus:four-year results of the look ahead trial[J].Arch Intern Med,2010,170(17):1566 -1575.DOI:10.1001/archinternmed.2010.334. [17]ZHENG G,XIA R,ZHOU W,et al.Aerobic exercise ameliorates cognitive function in older adults with mild cognitive impairment:a systematic review and meta-analysis of randomised controlled trials[J].Br J Sports Med,2016 ,50(23):1443-1450.DOI:10.1136/bjsports-2015-095699. [18]RAJANI S,ARCHANA R,INDLA Y R,et al.Beneficial effects of yogasanas and pranayama in limiting the cognitive decline in type 2 diabetes[J].Natl J Physiol Pharm Pharmacol,2017,7(3):232-235.DOI:10.5455/njppp.2017.7.0825508092016. [19]FIATARONE SINGH M A,GATES N,SAIGAL N,et al.The Study of Mental and Resistance Training(SMART) study-resistance training and/or cognitive training in mild cognitive impairment:a randomized,double-blind,double-sham controlled trial[J].J Am Med Dir Assoc,2014,15(12):873-880.DOI:10.1016/j.jamda.2014.09.010. [20]TEIXEIRA R B,MARINS J C,DE SA JUNIOR A R,et al.Improved cognitive,affective and anxiety measures in patients with chronic systemic disorders following structured physical activity[J].Diab Vasc Dis Res,2015,12(6):445-454.DOI:10.1177/1479164115602651. [21]TEIXEIRA R B,MARINS J C B,AMORIM P R S,et al.Evaluating the effects of exercise on cognitive function in hypertensive and diabetic patients using the mental test and training system[J].World J Biol Psychiatry,2017,28:1-10.DOI:10.1080/15622975.2017.1337222. [22]LUCHSINGER J A,PALMAS W,TERESI J A,et al.Improved diabetes control in the elderly delays global cognitive decline[J].J Nutr Health Aging,2011,15(6):445-449. [23]PINTANA H,APAIJAI N,PRATCHAYASAKUL W,et al.Effects of metformin on learning and memory behaviors and brain mitochondrial functions in high fat diet induced insulin resistant rats[J].Life Sci,2012,91(11/12):409-414.DOI:10.1016/j.lfs.2012.08.017. [24]HAFFINER S,TEMPROSA M,CRANDALL J,et al.Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance[J].Diabetes,2005,54(5):1566-1572. [25]CHEN F,DONG R R,ZHONG K L,et al.Antidiabetic drugs restore abnormal transport of amyloid-β across the blood-brain barrier and memory impairment in db/db mice[J].Neuropharmacology,2016,101:123-136.DOI:10.1016/j.neuropharm.2015.07.023. [26]NG T P,FENG L,YAP K B,et al.Long-term metformin usage and cognitive function among older adults with diabetes[J].J Alzheimers Dis,2014,41(1):61-68.DOI:10.3233/JAD-131901. [27]梁城铭,安刚,韩昕彤,等.二甲双胍联合有氧运动对2型糖尿病患者认知功能的改善作用[J].中国老年学杂志,2017,37(12):2958-2959.DOI:10.3969/j.issn.1005-9202.2017.12.043. LIANG C M,AN G,HAN X T,et al.Effect of metformin combined with aerobic exercise on cognitive function in patients with type 2 diabetes mellitus[J].Chinese Journal of Gerontology,2017,37(12):2958-2959.DOI:10.3969/j.issn.1005-9202.2017.12.043. [28]LIN Y,WANG K,MA C,et al.Evaluation of metformin on cognitive improvement in patients with non-dementia vascular cognitive impairment and abnormal glucose metabolism[J].Front Aging Neurosci,2018,27(10):227.DOI:10.3389/fnagi.2018.00227. [29]HSU C C,WAHLQVIST M L,LEE M S,et al.Incidence of dementia is increased in type 2 diabetes and reduced by the use of sulfonylureas and metformin[J].J Alzheimers Dis,2011,24(3):485-493.DOI:10.3233/JAD-2011-101524. [30]IMFELD P,BODMER M,JICK S S,et al.Metformin,other antidiabetic drugs,and risk of Alzheimer's disease:a population-based case-control study[J].J Am Geriatr Soc,2012,60(5):916-921.DOI:10.1111/j.1532-5415.2012.03916.x. [31]MOORE E M,MANDER A G,AMES D,et al.Increased risk of cognitive impairment in patients with diabetes is associated with metformin [J].Diabetes Care,2013,36(10):2981-2987.DOI:10.2337/dc13-0229. [32]KHANFAR M A,ABUKHADER M M,ALQTAISHAT S,et al. Pharmacophore modeling,homology modeling,and in silico screening reveal mammalian target of rapamycin inhibitory activities for sotalol,glyburide,metipranolol,sulfamethizole,glipizide,and pioglitazone[J].Mol Graph Model,2013,42:39-49.DOI:10.1016/j.jmgm.2013.02.009. [33]OSBORNE C,WEST E,NOLAN W,et al.Glimepiride protects neurons against amyloid-beta-induced synapse damage[J].Neuropharmacology,2016,101:225-236.DOI:10.1016/j.neuropharm.2015.09.030. [34]綦雯雯,贾凯英,孙达,等.吡格列酮对糖尿病大鼠中枢神经系统11β-羟类固醇脱氢酶1 型表达的影响[J].神经疾病与精神卫生,2017,17(3):184-186.DOI:10.3969/j.issn.1009-6574.2017.03.009. QI W W,JIA K Y,SUN D,et al.Effects of pioglitazone on expressions of 11β-hydroxysteroid dehydrogenase type 1 in central nervous system of diabetic rats[J].Journal of Neuroscience and Mental Health,2017,17(3):184-186.DOI:10.3969/j.issn.1009-6574.2017.03.009. [35]SEARCY J L,PHELPS J T,PANCANI T,et al.Long-term pioglitazone treatment improves learning and attenuates pathological markers in a mouse model of Alzheimer's disease[J].Alzheimers Dis,2012,30(4):943-961.DOI:10.3233/JAD-2012-111661. [36]SATO T,HANYU H,HIRAO K,et al.Efficacy of PPAR-gamma agonist pioglitazone in mild Alzheimer disease[J].Neurobiol Aging,2011,32(9):1626-1633.DOI:10.1016/j.neurobiolaging.2009.10.009. [37]于海燕,王群松,张梓威,等.吡格列酮治疗2 型糖尿病轻度认知功能障碍患者的临床疗效[J].中国老年学杂志,2017,37(17):4224-4226.DOI:10.3969/j.issn.1005-9202.2017.17.026. YU H Y,WANG Q S,ZHANG Z W,et al.Clinical efficacy of pioglitazone in the treatment of mild cognitive impairment in type 2 diabetes mellitus [J].Chinese Journal of Geriatrics,2017,37(17):4224-4226.DOI:10.3969/j.issn.1005-9202.2017.17.026. [38]LU C H,YANG C Y,LI C Y,et al.Lower risk of dementia with pioglitazone,compared with other second-line treatments,in metformin-based dual therapy:a population-based longitudinal study[J].Diabetologia,2018,61(3):562-573.DOI:10.1007/s00125-017-4499-5. [39]TALBOT K.Brain insulin resistance in Alzheimer's disease and its potential treatment with GLP-1 analogs[J].Neurodegener Dis Manag,2014,4(1):31-40.DOI:10.2217/nmt.13.73. [40]CHEN S,LIU AR,AN FM,et al.Amelioration of neurodegenerative changes in cellular and rat models of diabetes-related Alzheimer's disease by exendin-4[J].Age(Dordr),2012,34:1211-1224.DOI:10.1007/s11357-011-9303-8. [41]HOLSCHER C.Central effects of GLP-1:new opportunities for treatments of neurodegenerative diseases[J].J Endocrinol,2014,221(1):T31-41.DOI:10.1530/JOE-13-0221. [42]MCCLEAN P L,PARTHSARATHY V,FAIVRE E,et al.The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease[J].Neurosci,2011,31(17):6587-6594.DOI:10.1523/JNEUROSCI.0529-11.2011. [43]GEJL M,GJEDDE A,EGEFJORD L,et al.In Alzheimer's disease,6-month treatment with GLP-1 analog prevents decline of brain glucose metabolism:randomized,placebo-controlled,double-blind clinical trial[J].Front Aging Neurosci,2016 ,8:108.DOI:10.3389/fnagi.2016.00108. [44]洪世华,吴菊琴,方向南,等.GLP-1受体激动剂对2 型糖尿病合并阿尔茨海默病患者认知功能的影响[J].中国当代医药,2016 ,23(29):60-62. HONG S H,WU J Q,FANG X N,et al.Influence of GLP-1 receptor stimulant on the cognitive function in patients with type 2 diabetes complicated with Alzheimer disease [J].China Modern Medicine,2016,23(29):60-62. [45]张萌,张璐,李玉中,等.利拉鲁肽对2型糖尿病患者认知功能的影响及可能机制[J].中华糖尿病杂志,2014,6(2):91-96.DOI:10.3760/cma.j.issn.1674-5809.2014.02.007. ZHANG M,ZHANG L,LI Y Z,et al.Effects of liraglutide on the cognitive function in patients with type 2 diabetes mellitus and the underlying mechanism [J].Chin J Diabetes Mellitus,2014,6(2):91-96.DOI:10.3760/cma.j.issn.1674-5809.2014.02.007. [46]CAI H Y,HOLSCHER C,YUE X H,et al.Lixisenatide rescues spatial memory and synaptic plasticity from amyloid beta protein-induced impairments in rats[J].Neuroscience,2014,277:6-13.DOI:10.1016/j.neuroscience.2014.02.022. [47]PIPATPIBOON N,PINTANA H,PRATCHAYASAKUL W,et al. DPP4-inhibitor improves neuronal insulin receptor function,brain mitochondrial function and cognitive function in rats with insulin resistance induced by high-fat diet consumption[J].Eur J Neurosci,2013,37(5):839-849.DOI:10.1111/ejn.12088. [48]KOSARAJU J,MURTHY V,KHATWAL R B,et al.Vildagliptin:an anti-diabetes agent ameliorates cognitive deficits and pathology observed in streptozotocin-induced Alzheimer's disease[J].J Pharm Pharmacol,2013,65(12):1773-1784.DOI:10.1111/jphp.12148. [49]黄文湧,韩志琰,杨敬源,等.老年糖尿病患者降糖治疗与认知功能的关系[J].中国糖尿病杂志,2009,17(11):850-852.DOI:10.3969/j.issn.1006-6187.2009.11.017. HUANG W Y,HAN Z Y,YANG J Y,et al.The relationship between diabetic treatment and cognitive function among the elderly[J].Chin J Diabetes,2009,17(11):850-852.DOI:10.3969/j.issn.1006-6187.2009.11.017. [50]ARAKI A.Insulin therapy in elderly patients with diabetes mellitus[J].Nihon Ronen Igakkai Zasshi,2004,41(2):157-160. [51]RDZAK G M,ABDELGHANY O.Does insulin therapy for type 1 diabetes mellitus protect against Alzheimer's disease?[J].Pharmacotherapy,2014,34(12):1317-1323.DOI:10.1002/phar.1494. [52]杨雁,马德琳,王玉萍,等.鼻腔滴入胰岛素改善2型糖尿病大鼠海马阿尔茨海默病样改变[J].中国病理生理杂志,2013,29(1):56-61.DOI:10.3969/j.issn.1000-4718.2013.01.009. YANG Y,MA D L,WANG Y P,et al.Intranasal insulin treatment ameliorates Alzheimer disease-like changes in hippocampus in a rat model of type 2 diabetes[J].Chinese Journal of Pathophysiology,2013,29(1):56-61.DOI:10.3969/j.issn.1000-4718.2013.01.009. [53]FREIHERR J,HALLSCHMID M,FREY W H 2nd,et al.Intranasal insulin as a treatment for Alzheimer's disease:a review of basic research and clinical evidence[J].CNS Drugs,2013,7(7):505-514.DOI:10.1007/s40263-013-0076-8. [54]CRAFT S,BAKER L D,MONTINE T J ,et al.Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment:a pilot clinical trial[J].Arch Neurol,2012 ,69(1):29-38.DOI:10.1001/archneurol.2011.233. [55]FEART C,SAMIERI C,RONDEAU V,et al.Adherence to a Mediterranean diet,cognitive decline,and risk of dementia[J].JAMA,2009 ,302(6):638-648.DOI:10.1001/jama.2009.1146. [56]ANGEVAREN M,AUFDEMKAMPE G,VERHAAR H J,et al.Physical activity and enhanced fitness to improve cognitive function in older people without known cognitive impairment[J].Cochrane Database Syst Rev,2008,16(3):CD005381.DOI:10.1002/14651858.CD005381.pub3. [57]PODOLSKI N,BRIXIUS K,PREDEL H G,et al.Effects of regular physical activity on the cognitive performance of type 2 diabetic patients:a systematic review[J].Metab Syndr Relat Disord,2017,15(10):481-493.DOI:10.1089/met.2017.0120. [58]中国痴呆与认知障碍诊治指南写作组.2018中国痴呆与认知障碍诊治指南(四):认知障碍疾病的辅助检查[J].中华医学杂志,2018,98(15):1130-1142.DOI:10.3760/cma.j.issn.0376-2491.2018.15.003. Chinese dementia and cognitive impairment guidelines writing group.2018 guidelines for diagnosis and treatment of dementia and cognitive impairment in China(four):auxiliary examination for cognitive impairment[J].Natl Med J China,2018,98(15):1130-1142.DOI:10.3760/cma.j.issn.0376-2491.2018.15.003. [59]Consensus report of the Working Group on:"Molecular and Biochemical Markers of Alzheimer's Disease".The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group [J].Neurobiol Aging,1998,19(2):109-116. [60]中国痴呆与认知障碍诊治指南写作组.2018中国痴呆与认知障碍诊治指南(二):阿尔茨海默病诊治指南[J].中华医学杂志,2018,98(13):971-977.DOI:10.3760/cma.j.issn.0376-2491.2018.13.004. Chinese dementia and cognitive impairment guidelines writing group.2018 guidelines for diagnosis and treatment of dementia and cognitive impairment in China(two):guidelines for the diagnosis and treatment of alzheimer's disease [J].Natl Med J China,2018,98(13):971-977.DOI:10.3760/cma.j.issn.0376-2491.2018.13.004. |
[1] | ZHANG Tianyu, YU Haibo, CHEN Fei, LI Xin, ZHANG Jiajia, ZHAN Xiaokai, SHEN Man, TANG Ran, FAN Sibin, ZHAO Fengyi, HUANG Zhongxia. Meta-analysis of the Efficacy and Safety of Systemic Treatment for POEMS Syndrome [J]. Chinese General Practice, 2025, 28(27): 3447-3455. |
[2] | CUI Yiyuan, YAN Yijing, WANG Ying, MENG Xiangju, ZHANG Qinglin, LIU Lixing, LI Sicong, FENG Li, The Working Group for the Clinical Practice Guideline for the Cancer-related Fatigue with Integrated Traditional Chinese and Western Medicine. Clinical Practice Guideline for the Integrated Traditional Chinese and Western Medicine Diagnosis and Treatment of Cancer-related Fatigue [J]. Chinese General Practice, 2025, 28(27): 3345-3358. |
[3] | ZHANG Yunuo, LI Ruibin, WANG Wei. Correlation Analysis of Serum Nesfatin-1 and Ghrelin Levels with Glycolipid Metabolism and Type 2 Diabetes Mellitus [J]. Chinese General Practice, 2025, 28(26): 3264-3270. |
[4] | ZHANG Ruimin, DONG Zheyi, LI Shuang, WANG Qian, CHEN Xiangmei. Traditional Chinese Medicine Factors Associated with Diabetic Nephropathy Diagnosed by Renal Biopsy [J]. Chinese General Practice, 2025, 28(26): 3307-3313. |
[5] | TANG Shangfeng, HUANG Yangzhen, ZHENG Yanxi, PAN Yangyang, XIONG Zhongbao, QING Hua, SONG Jia, WEI Yilin, DONG Heng, WANG Chunying, CHEN Manwei, ZHANG Kangkang. Specification for the Integration of Healthcare and Prevention Services in Diabetes at the Primary Level [J]. Chinese General Practice, 2025, 28(25): 3096-3103. |
[6] | PAN Qi, REN Jingjing, MA Fanghui, HU Mengjie. Survey of General Practitioners' Cognition and Needs for AI Assisted Diagnosis and Treatment Systems [J]. Chinese General Practice, 2025, 28(25): 3127-3136. |
[7] | YANG Chen, CHEN Tong, ZHANG Lifang, ZHANG Hongxu, LI Pengfei, ZHANG Xuejuan. Prognostic Impact of Dapagliflozin in Elderly Breast Cancer Survivors with Heart Failure with Preserved Ejection Fraction and Type 2 Diabetes [J]. Chinese General Practice, 2025, 28(24): 3053-3058. |
[8] | WANG Rupeng, NAN Jing, HU Yiran, YANG Shenghua, JIN Zening. Predictive Value of the Triglyceride-Glucose Body Mass Index for Slow Flow/No-reflow Phenomenon in Patients with Type 2 Diabetes Mellitus and Acute Myocardial Infarction Undergoing Emergency Percutaneous Coronary Intervention [J]. Chinese General Practice, 2025, 28(24): 2985-2992. |
[9] | LI Miaoxiu, ZHU Bowen, KONG Lingjun, FANG Min. Progress in Research on Clinical Assessment Tools for Conservative Treatment of Adolescent Idiopathic Scoliosis [J]. Chinese General Practice, 2025, 28(24): 3079-3088. |
[10] | XIAO Yao, WAN Jun. Treatment of Venous Thromboembolism in Special Populations with Direct Oral Anticoagulants [J]. Chinese General Practice, 2025, 28(24): 3066-3071. |
[11] | National Clinical Research Center for Infectious Diseases Jiangxi Branch, Jiangxi Provincial Key Laboratory of Tuberculosis. Expert Consensus on the Treatment of Pulmonary Tuberculosis Complicated with Chronic Hepatitis B Virus Infection [J]. Chinese General Practice, 2025, 28(24): 2961-2967. |
[12] | LIU Yueying, WANG Xueli, LIU Yuqiu, WEI Limin. Correlation of Fasting C-peptide to Diabetes Duration Ration and Type 2 Diabetes Mellitus Combined with Metabolism-related Fatty Liver Disease [J]. Chinese General Practice, 2025, 28(23): 2852-2860. |
[13] | WANG Peng, QIU Lixia, XU Shanshan, ZHANG Yang, ZHANG Jing, DU Xiaofei. Advances in the Co-management of Metabolism Dysfunction-associated Fatty Liver Disease and Type 2 Diabetes Mellitus [J]. Chinese General Practice, 2025, 28(23): 2846-2851. |
[14] | BAI Xue, CHEN Qianqian, LI Jie. Innovative Practices in Chronic Disease Management: a New Model for Generalist-Specialist Combination Management of Diabetes and Metabolic Dysfunction-associated Fatty Liver Disease [J]. Chinese General Practice, 2025, 28(23): 2841-2845. |
[15] | TANG Xiaorui, XU Jingjing, GU Zijun, WANG Qingyu, LIN Zheng, ZHU Qiurui, LEI Yang. The Reliability and Validity of the Chinese Version of Self-Care of Diabetes Inventory [J]. Chinese General Practice, 2025, 28(21): 2643-2651. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||